India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
10/02/2026 03:10
Feb 10 (Reuters) - Indian drugmaker Lupin LUPN.NS said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma 4503.T over the bladder disorder drug Mirabegron, allowing it to continue selling the product in the United States. Under the agreement, Lupin and its U.S. unit will pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027, the company said in an exchange filing. The settlement resolves Lupin's pending litigation with Astellas and enables the company to continue marketing Mirabegron in the United States. Lupin had previously disclosed the patent dispute with the Japanese drugmaker last April over its generic version of Myrbetriq, Astellas' overactive bladder drug. (Reporting by Surbhi Misra in Bengaluru; Editing by Sherry Jacob-Phillips) ((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn